BrainStorm’s NurOwn: Cell Therapy Lacks Substantial Evidence Of Efficacy In ALS, US FDA Says

 
• By Sue Sutter
Floor
The ALSFRS-R 'floor effect' will be a topic of debate at the 27 September advisory committee review of NurOwn. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers